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Objective: To characterize the causes of mortality and standardised mortality ratio in a cohort of 
patients with Systemic Sclerosis (SSc). 
 
Methods: A cohort of 132 patients enrolled at the Waikato Systemic Sclerosis clinic was 
prospectively followed from 2005 to 2016. Patient demographics, diagnoses and lab reports were 
used to assess risk of mortality and generate standardised mortality ratios (SMR). Survival was 
analysed using Kaplan-Meier methods. 
 
Results: Of the cohort of 132 patients, 20 (15%) were deceased by the end of the study period. The 
median age of diagnosis and death was 52 years (range 13-86) and 71 years (range 42-87) 
respectively. Seventy percent of deaths were SSc related and the leading causes of death were due 
to pulmonary arterial hypertension (PAH), interstitial lung disease (ILD) and scleroderma renal crisis 
(SRC).  Patients diagnosed after the age of 60, had renal or cardiac manifestations were associated 
with a significantly increased risk of mortality. The overall SMR was 2.59 (95% CI 1.67-4.01) and was 
higher in those with diffuse versus limited SSc (6.46, 95% 3.08-13.54 vs 1.93, 95% CI 1.10-3.41) and 
males (4.17, 95% CI 1.74-10.02 vs 2.30, 95% CI 1.39-3.81). 
 
Conclusion: This study demonstrated an increased risk of mortality in patients with SSc relative to 
that of the general population. An excess in risk was observed particularly in those with diffuse SSc 
and in males. Renal and cardiac involvement were found to be significant indicators of mortality and 
















Systemic sclerosis (SSc) is a chronic heterogeneous autoimmune connective tissue disorder 
characterized by specific antibody production, vasculopathy and fibrosis of the skin and other 
internal organs. This condition is associated with higher mortality and morbidity, on account of its 
multisystem involvement. Pathogenesis of SSc is not completely understood and current treatments 
are seldom effective in preventing disease progression 1-3.  
 
SSc is classified into two defined subsets, limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc 
(dcSSc) based on the extent of skin involvement. DcSSc is frequently more aggressive and involves 
multiple organ systems such as the lungs, heart and kidneys at an early stage 1, 4. Major known  
causes of mortality in SSc include pulmonary arterial hypertension (PAH), pulmonary fibrosis (PF), 
scleroderma renal crisis (SRC), malabsorption and cardiomyopathy 5. Recommendations have been 
made regarding appropriate screening to facilitate early detection of these complications 6-8. 
 
Several studies have explored the mortality in SSc in various geographical areas from America, 
Australia, Canada, Europe, Japan, and Singapore 9-23.  
 
We aimed to assess and analyse the predictors of mortality in our cohort of SSc patients diagnosed 




Data Collection  
The Waikato Hospital patient database was used as the primary source for extracting data. This 
database was based on information that had been gathered prospectively from the Waikato 
Systemic Sclerosis Cohort from 2005. The clinic operates in a secondary and tertiary capacity, 
drawing patients from neighbouring regions. Both inpatients and out-patients with systemic sclerosis 
are included in the cohort. Sources of information including clinical notes, referral letters, laboratory 
results and admission histories were consulted. Where information was not available for referred 
patients from surrounding regions, clinical records were requested from their respective hospitals 
and practices. The date of diagnosis was defined as the date SSc was formally diagnosed and first 
documented in the patient’s clinical notes. Whilst this was available for the majority of patients, 
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when unclear, laboratory results were reviewed to assess the dates of antibody testing to serve as a 
proxy and approximate the date of diagnosis.   
 
Additional information was collected with the patient’s consent for The European Scleroderma Trials 
and Research Group (EUSTAR) registry. This included demographic data and measures such as a 
modified Rodnan Skin Score (mRSS). Data was collected up until the 14th of December 2016, which 
defined the censoring date for the mortality estimates. The current study has been approved by the 
NZ Health and Disability Ethics Committee. 
 
All patients fulfilled the 2013 American College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) classification criteria for systemic sclerosis 24. Further classification into 
lcSSc, dcSSc and scleroderma overlap syndrome (SOS) subtypes of systemic sclerosis were made 
according to LeRoy’s criteria 25. Patients who exhibited features of other connective tissue disease 
overlapping with systemic sclerosis were classified as SOS.  
 
Comorbidities were categorised into three groups; renal, cardiac and pulmonary manifestations. 
Renal comorbidities were defined as a documented diagnosis of renal failure and SRC. Cardiac 
comorbidities were defined as heart failure, cardiomyopathy and pericardial effusions whilst 
respiratory comorbidities included  PAH and ILD 2. 
 
Antibodies were detected using the EUROIMMUN Systemic Sclerosis (Nucleoli) EUROLINE (IgG) test 
kit, to assess for the presence of specific SSc antibodies. These included Scl-70, CENP-A, CENP-B, 
RP11, RP115, Fib, NOR90, Th/To, PM100, PM75, Ku, PDGFR and Ro-52 26. 
 
Mortality data 
Mortality data was collected from the database based on the established date of death recorded 
from confirmed death certificates. The cause of death was identified in the patient’s clinical 
documentation. Where uncertain, causes of death and relation to SSc were adjudicated by two 
consultant rheumatologists (KS & DW). A Standardised Mortality Ratio (SMR) was derived from the 
cohort comparing the relative rate of mortality between the study group and the general population 
within the study period. Annual death rates by age (5 year groups) and gender from 1976 to 2015 
were provided by Statistics New Zealand. Statistics New Zealand is a government organisation tasked 
with the collection and management of statistical data, in areas such as the economy, society and 
the environment 27. Mortality rates for 2016 were assumed to be the same as 2015. Mortality rates 
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for those aged 13-19 (3 patients were diagnosed at age <20 years) were assumed to be the same as 
those aged 20-24 and birthdays were assumed to be on the 1st of January each year. 
 
Statistical analysis 
Data was entered and analysed using Microsoft Excel and IBM SPSS Statistics version 23. Descriptive 
statistics were computed as mean (standard deviation) or median (range) where appropriate. 
Survival analysis for the cohort was completed using the Kaplan-Meier method and comparisons 
between groups were tested using the Log Rank test. For all statistical tests a P value of <0.05 was 




A total of 132 individuals who fulfilled the ACR/EULAR criteria for systemic sclerosis were identified 
and recruited for this study. The cohort consisted of 115 female patients (87%) and 17 male patients 
(13%). The majority of patients identified as NZ European ethnicity (n=99, 77%), followed by Other 
European (n=11, 39%), Māori  (n=8, 6%), Indian (n=6, 5%), Asian (n=3, 2%), Tongan (n=1, 1%), and 
four were not identified (3%). The median age of diagnosis was 52 years (range 13-86), with the 
median duration of follow up being 7 years (range 0-41). Median age of first non-Raynaud 
phenomenon was 50 (range 20-78). A total of 1287 patient follow up years was recorded. In 
assessing smoking status for patients, 54 (41%) patients have smoked at least once in the past, 67 
(51%) have never smoked and 11 (8%) are unaccounted for (table 1).   
 
Diagnosis and relevant investigations 
In diagnosis of specific SSc subtypes, 89 (67.4%) were diagnosed with lcSSc, 33 (25.0%) with dcSSc 
and 10 (7.6%) with SOS. The average maximum mRSS for patients with lcSSc was 5.53 (SD 4.25), 
dcSSC 17.50 (SD 11.92) and SOS 3.22 (SD 2.54). Measures were unavailable for 10 patients. Of the 
cohort assessed, 127 (96%), 42 (32%) and 15 (18%) tested positive for Anti-nuclear antibodies (ANA), 
Anti-centromere antibodies (ACA) and Anti-Scl-70 antibodies (Scl-70) respectively (table 1). 
 
Mortality 
By the end of the study period (December 14, 2016) 20 patients had died (15 female, 5 male). Based 
on lcSSc, dcSSc and SOS subtypes, 12 (13.5%), 7 (21.2%) and 1 (10.0%) individual(s) respectively were 
deceased. The median age at death was 71 years (range 42-87). The median age at death for those 
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with lcSSc was 70 years (range 42-87), dcSSc 71 years (range 67-87) and a single -patient with SOS 
passed away at the age of 69.  
 
Sixty-one patients were found with at least one comorbidity relevant to the renal, cardiac and 
pulmonary systems. Of the total cohort, 11 (8.3%) had renal involvement, 17 (12.9%) had cardiac 
involvement and 50 (37.9%) had pulmonary involvement (table 1). Deaths were then categorised as 
related or unrelated to SSc: 65% of deaths recorded during the study period were SSc related. Of 
these, PAH was the leading cause of death (35%) followed by ILD (15%) and SRC (10%). Further SSc 
related deaths in the cohort occurred from factors including sepsis (5%) and severe malnutrition due 
to gastrointestinal involvement (5%).  
 
Deaths unrelated to SSc included prostate cancer, metastatic melanoma, other malignancies, 
ischaemic heart disease (IHD), and traumatic subdural haemorrhage 2 (table 2). 
 
Survival 
An age and gender adjusted SMR was calculated for the cohort and further sub-categories according 
to gender and SSc subtype. The SMR for the cohort studied demonstrated a 2.59 (95% CI 1.67-4.01, 
p<0.001) times increased risk of mortality compared the national population (table 3). Differences 
were observed between the SMR of lcSSc (1.93, 95% CI 1.10-3.41) and dcSSc (6.46, 95% CI 3.08-
13.54) subtypes. SMR for females (2.30, 95% CI 1.39-3.81) was lower than males (4.17 95% CI 1.74-
10.02) .  
 
Kaplan-Meier curves were also generated and the results of log rank tests were used to analyse the 
association between patient features and mortality within the cohort. Renal involvement (𝑥𝑥2=14.84, 
P<0.001), cardiac involvement (𝑥𝑥2=8.44, P=0.02), pulmonary involvement (𝑥𝑥2=5.63, P= 0.018), being 
diagnosed after the age of 60 (𝑥𝑥2=33.50, P<0.001) and maximum mRSS (𝑥𝑥2=91.48, P<0.001) showed 
significant effects on survival (table 3).  
 
Discussion 
This is the first study to date investigating survival in a New Zealand cohort of SSc patients. The 
overall SMR obtained from our cohort was 2.59, comparable to several studies in Japan (2.76), 
Denmark (2.90) and Canada (2.69); this was within reasonable expectations as highlighted by an 
international meta-analysis in 2012 observing a pooled SMR of 3.53 and another done in 2005 with 
SMRs ranging from 1.5 to 7.2 10, 15, 17, 19, 23. These results reinforce the notion that an excess risk of 
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mortality can be associated with SSc relative to the general population. The dcSSc demonstrated a 
significant difference in mortality in our patients compared to those with lcSSc, consistent with the 
prognosis of dcSSc and the findings of previous literature 9, 10, 15, 19, 21, 22. In comparing SMRs for 
gender, no significant differences were seen between males and females, also in line with findings 
reported in studies such as those by Hesselstrand, Jacobsen and Scussel-Lozentti 17, 19, 20, 23. In 
contrast, differences in gender have been noted in some studies whereby male gender was 
associated with a higher SMR. Results observed by Hashimoto and Hussein have indicated a poorer 
prognosis of SSc in male patients attributed to multisystem organ involvement. These findings 
however were inconclusive and acknowledged the potential of confounding factors unrelated to 
gender 10, 28. It is worth acknowledging that these comparisons should not be overestimated due to 
the relatively few participants in our study resulting in wide confidence intervals. Despite the 
increased overall SMR in the cohort, no other sub-category showed significant differences in 
mortality compared to the general population. 
 
In our study, the presence of renal, cardiac and pulmonary manifestations within the cohort were 
significantly associated with increased mortality as demonstrated through Kaplan-Meier analysis 
(table 3). In observing the distribution of comorbidities, the percentage of patients with lung 
involvement (38%) appeared similar to that of other studies which have reported a range of 24-50%. 
Cardiac involvement, observed in 24% of our patient cohort was also relatively comparable to figures 
reported in literature varying from 10-40%. Likewise the rates of renal comorbidities in our study 
(8%) were consistent with the range reported in international literature of 6-17%, in addition to  
uniform counts for SRC at approximately 3% (table 4) 9, 10, 13, 17, 18, 22. With the exception of a study 
conducted by Ferri et al (2002) which showed lung involvement at 81% and SRC counts at 10% of the 
cohort, findings were otherwise relatively consistent across all studies 9-15, 17-23. 
 
Previous studies have shown that pulmonary, renal and cardiac involvement are associated with 
increased mortality and poor prognosis 5, 12, 15, 21, 23. It is possible the lack of significance shown by 
pulmonary involvement in our study could be attributable to various limitations of our study 
discussed later on. 
 
The percentage of deceased patients in our study (15%) appeared to be in the lower ranges 
compared to other studies observed. Of these deaths, however, SSc related deaths (70%) was 
relatively similar across international cohorts (table 4) 12, 15, 23. This was consistent with the recent 
meta-analysis of international studies with 27% of patients reported deceased and 64% SSc related 
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deaths 23. Additionally, of the deaths in our cohort, PAH (30%) and ILD (15%) were notably the most 
common followed by SRC (10%) (table 3). This may be suggestive of the trends observed by Steen 
and Medsger: an increasing proportion of deaths due to PAH and pulmonary fibrosis (PF) with fewer 
SRC related deaths following advances in screening and the introduction of ACE inhibitors 5.  
 
Several limitations of this study exist. One of the difficulties encountered in the study was in relation 
to the size of the cohort and implications on validity and comparability. With a total patient number 
of 132 with no loss of follow up, this was among the smaller studies done with relation of SSc and 
mortality. Nonetheless, taking into consideration the relatively small size of New Zealand’s 
population (approximately 4.8 million), these results give a reasonable indication of population 
representation 29. Accordingly, statistical methods involving the use of Kaplan-Meier curves and Cox 
proportional hazards models to assess mortality were limited in their power to explore associations 
within our cohort. Additionally, months lived with SSc from the age at diagnosis was used as a 
baseline measure of survival. This gives rise to an element of age dependency in our cohort when 
comparing results to other studies. However, the distribution of the mean age at diagnosis in 
international cohorts appear to be similarly clustered around 50 years and therefore use of this 
measure would not affect comparisons to a significant degree (table 4). It is possible that those with 
milder disease will not be referred for secondary or tertiary care and would not therefore form part 
of this cohort with SSc. However, this established clinic is recognised as local centre of excellence in 
the management of systemic sclerosis and it is routine practice in neighbouring centres to refer all 
potential cases for assessment. The demographics and patient characteristics of this cohort are 
consistent with other published cohorts reinforcing that this is a representative cohort. 
 
With regards to ethnicities, New Zealand is a predominantly European country with a growing Māori, 
Pacific Peoples and Asian population 30. As a consequence, analysis on potential ethnic disparities in 
the risk of mortality for SSc could not be achieved to a satisfactory level given the small numbers in 
our cohort. To improve the accuracy of our analysis, Māori and Pacific ethnic groups were combined 
as traditionally these groups have faced similar inequities in health outcomes 31, 32. Results were 
suggestive of an earlier onset of SSc in this group which is in line with other studies who made 
comparisons with ethnic minorities 16. At present, further analysis in this area was not possible given 
the number of patients in the study but provides an avenue for further research to pursue in later 






In summary, our cohort had a significantly higher rate of mortality compared to that of the general 
population. Those with dcSSc, renal involvement, cardiac involvement and diagnosis after the age of 
60 demonstrated a marked increase in mortality within our cohort. Leading causes of death included 
PAH followed by ILD and SRC. Our results suggest consistent practices and management of SSc 
within our cohort compared to that of international studies.  
In identifying these risk factors within our cohort, increased awareness, education and management 
of screening practices can be undertaken to reduce SSc related mortality.  
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± Size of patient group stated in brackets (n) 
 
Whole cohort (n=132) Living (n= 112) Deceased (n=20) 
 Demographics 
    Females 115 (87.1) 100 (89.3) 15 (75.0) 
 Males  17 (12.9) 12 (10.7) 5 (25.0) 
 Median age (range) 63 (20-87) 61 (20-85) 71 (42-87)  
Median age at diagnosis (range) 52 (13-86) 51 (13-81) 67 (86-36) 
 Median duration of disease (range) 7.1 (0-41) 7.7 (0-41) 2.5 (0-30) 
 Maximum mRSS (S.D.) 8.6 (8.9) 8.2 (8.1) 11.4 (13.5) 
      Subtype of SSc 
     - Limited SSc 89 (67.4) 77 (68.8) 12 (60.0) 
  - Diffuse SSc 33 (25.0) 26 (23.2) 7 (35.0) 
  - Overlap 10 (7.6) 9 (8.0) 1 (5.0) 
      Serology ± 
     - Anti-Scl-70 (n=83) 15 (18.1) 14 (16.9) 1 (6.7) 
  - Anti-Centromere (n=82) 42 (51.2) 39 (47.6) 3 (15.0) 
  - Anti-nuclear (n=130) 127 (97.7) 108 (83.1) 17 (89.5) 
  - RNA Pol III (n=74) 14 (18.9) 12 (16.2) 2 (10.0) 
  - RP 155 (n=74) 13 (18.1) 11 (14.9) 2 (10.0) 
      Organ involvement 
     - Pulmonary 50 (37.9) 38 (10.7) 12 (60.0) 
  - Cardiac 17 (12.9) 9 (8.0) 8 (40.0) 
  - Renal 11 (8.3) 5 (4.5) 6 (30.0) 
      Smoking status 




Table 2: Causes of death for the 20 patients with SSc 
 
Cause of death Number = 20 (n%) 
Related to SSc 
 Pulmonary arterial hypertension  7 (35) 
Interstitial lung disease 3 (15) 
Scleroderma renal crisis 2 (10) 
Malnutrition 1 (5) 
  
  Unrelated to SSc 
 Ischemic heart disease (CAD) 1 (5) 
Prostate cancer 1 (5) 
Traumatic subdural haemorrhage 1 (5) 
Suspected malignancy 1 (5) 
Metastatic melanoma 1 (5) 
Infection and dementia 1 (5) 









Standardised Mortality Ratios 
    
 
Observed Expected SMR 95% CI 
Cohort 20 7.73 2.59 1.67-4.01 
lcSSc 12 6.20 1.93 1.10-3.41 
dcSSc 7 1.08 6.46 3.08-13.54 
SOS 1 0.44 2.27 0.11-11.19 
Females 15 6.53 2.30 1.39-3.81 
Males 5 1.19 4.17 1.74-10.02 
      
    
 










 Gender 3.5 0.061   
 Māori vs non-Māori 0.2 0.636   
 Cardiac involvement 9.7 0.02   
 Pulmonary involvement 5.6 0.018   
 Renal involvement 14.8 <0.001   
 Diagnosed after the age of 60 33.5 <0.001   
 Maximum mRSS 91.5 <0.001   
 Ever smoked 0.1 0.824   
 Use of any DMARD 0.2 0.596    
   Scl-70 0.3 0.598 
ANA 2.6 0.110 
ACA 0.6 0.431 
RP11 0.3 0.572 
RP155 1.0 0.314 
Ro52 1.4 0.231 
NOR90 0.2 0.632 
Fib 0.2 0.682 
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Table 4: Comparisons of international cohorts 
 



























             Total patients 132 2691 1645 786 405 706 223 251 249 344 309 1012 349 204 
Female 115 (87.1) 2230 (82.9) 1320 (80.2) 630 (80.2) 376 (92.8) 591 (83.7) 179 (87.7) 220 (87.6) 178 (71.5) 278 (81) 266 (86.1) 895 (88.5) 304 (87) 182 (89) 
lcSSc 89 (67.4) 1705 (63.4) - 501 (63.7) 273 (67.4) 460 (65.2) 164 (80.4) 200 (79.7) 186 (74.7) 226 (66) 152 (49.2) 407 (64) 122 (35) 121 (59) 
dcSSc 33 (25.0) 713 (26.5) 734 (44.6) 152 (19.3) 132 (32.6) 246 (34.8) 59 (26.5) 51 (20.3) 63 (25.3) 118 (34) 29 (9.4) 89 (14) 133 (38) 62 (31) 
SOS 10 (7.6) - - 53 (6.7) - - - - - - - - 91 (26) 21 (10) 
Mean age at 
diagnosis (S.D.) 51.4 (15.6) 50.1 - 46.7 (16.2) - 46.1 51.6 (8.8) 46.2 (15) 49.6 (13.8) - 49.2 (12.7) - 46.2 (15) 49 (17) 
Median age at 
diagnosis (range) 52 (13-86) (47.1-59.8) - - 47 - - - - - - - - - 
               Organ involvement 
              Lung 50 (37.9) 890 (43.2) 280 (31.7) - 204 (50.4) - - - - - 74 (23.9) 515 (81) - - 
- ILD - - - - - - 65 (32.3) 168 (66.9) - - - - - 78 (38) 
- PAH - - - 40 (7.6) 65 (16.0) - 23 (11.6) 3 (1.62) - - - - - 31 (15) 
Heart 17 (12.9) 447 (24.6) 165 (10.1) - 79 (19.6) - 25 (13.2) 36 (14.3) - - 28 (9.1) 223 (35) - 82 (40) 
Renal 11 (8.3) - 172 (10.5) - - - - 42 (16.7) - - - - - 12 (6) 
- SRC 3 (2.3) - - 19 (3.6) 13 (3.2) - 5 (2.8) - - - 6 (2.0) 64 (10) - 6 (3) 
Gastrointestinal - - - - 187 (46.4) - 187 (83.9) 188 (74.9) - - - - - 114 (56) 
               Serology 
              Scl-70+ 15 (18.1) 337 (22.8) 315 (25.3) 47 (10.7) 82 (23.3) 39 (19.6) 33 (16.2) 90 (36.6) - - 37 (12) 229 (36) - 46 (23) 
ACA+ 42 (51.2) 499 (33.8) 309 (22.3) 199 (49.4) 127 (36.1) 112 (22.1) 96 (47.1) 95 (38.6) - - 135 (43.7) 248 (39) - 75 (38) 
ANA+ 127 (97.7) - - - - 482 (89.3) - 61 (24.8) - - - 127 (20) - 187 (93) 
               Mortality 
              SMR 2.59 3.53 1.5-7.2 1.46 2.76 - 1.34 - 4.59 2.9 2.69 - - - 
Number of deaths 20 (15.2) 732 (27.2) 578 (35.1) 331 (42.1) 86 (21.2) 215 (30.5) 53 (23.6) 20 (8.6) 49 (19.7) 
160 
(46.5) 66 (21.3) 
279 
(27.6) 35 (10) 44 (23) 
Related deaths (n% 
of deaths)* 13 (65.0) - - - - - 19 (30) 12 (60.0) 15 (30.6) 41 (88.2) 35 (53) 87 (52) 20 (57.1) 36 (81.8) 
               *Numbers were inclusive of categories definitely SSc related and probably SSc related where applicable 
          
 
